ADCP2检测试剂盒 原装进口，现货促销

 ADCP2检测试剂盒 原装进口，现货促销

DPP4''DPPIV''二肽基肽酶4''二肽基肽酶IV''ADCP-2''CD26''ADABP''ADCP2''TP103

货号BML-AK499

DPPIV drug discovery kit    Enzo lifescience BML-AK499；二肽基肽酶 4 /二肽基肽酶IV  检测试剂盒，原装进口，现货供应！

The DPPIV Drug Discovery Kit is a complete assay system designed to screen DPPIV inhibitors'' providing enough material to perform at least 96 assays. DPPIV (DPP4'' CD26) is a member of the class of proteases known as prolyl peptidases'' which cleave proteins after proline residues and is thought to play roles in diabetes'' cancer'' and autoimmune diseases'' making it a target for drug discovery.

The kit contains both a chromogenic substrate (H-Gly-Pro-pNA; K_m=114 µM) and a fluorogenic substrate (H-Gly-Pro-AMC; K_m=50 µM).

Cleavage of the p-nitroaniline (pNA) from the colorimetric substrate increases absorbance at 405 nm. The fluorimetric assay is based on the cleavage of 7-amino-4-methylcoumarin (AMC) moiety from the C-terminus of the peptide substrate'' which increases its fluorescence intensity at 460 nm. The kit is useful to screen inhibitors of DPPIV'' a potential therapeutic target. A DPPIV inhibitor'' P32/98 (K_I=130 nM12)'' is included for use as a control. Other DPP enzymes are available for specificity profiling.

Product Specification

相关文献：

Product Literature References

16'' 17-Dihydro-17b-hydroxy isomitraphylline alkaloid as an inhibitor of DPP-IV'' and its effect on incretin hormone and β-cell proliferation in diabetic rat: A. Shukla'' et al.; Eur. J. Pharm. 47'' 512 (2012)'' Application(s): Measurement of inhibition of DPPIV by DHIM'' Abstract;

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent'' long-acting'' orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes: D. J. Augeri et al.; J. Med. Chem. 48'' 5025 (2005)'' Abstract;

CD26/dipeptidyl peptidase IV and its role in cancer: B. et al.; Histol. Histopathol. 19'' 1345 (2004)'' Abstract;

CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy: U. Aytac et al.; Curr. Drug. Targets Immune Endocr. Metabol. Disord. 4'' 11 (2004)'' Abstract;

Dipeptidyl peptidase IV inhibitors for the treatment of diabetes: A. E. Weber et al.; J. Med. Chem. 47'' 4135 (2004)''Abstract;

N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on enzyme activity'' homodimer formation'' and adenosine deaminase binding: K. Aertgeerts et al.; Protein Sci. 13'' 145 (2004)'' Abstract;

Dipeptidyl peptidase IV (CD26) activity in the hematopoietic system: differences between the membrane-anchored and the released enzyme activity: D. A. Pereira et al.; Braz. J. Med. Biol. Res. 36'' 567 (2003)'' Abstract;

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats: J. A. Pospisilik et al.; Diabetes 52'' 741 (2003)'' Abstract;

Prolyl peptidases: a serine protease subfamily with high potential for drug discovery: J. S. Rosenblum et al.; Curr. Opin. Chem. Biol. 7'' 496 (2003)'' Abstract;

Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV: R. Thoma et al.; Structure 11'' 947 (2003)'' Abstract;

On the regulatory role of dipeptidyl peptidase IV (=CD=adenosine deaminase complexing protein) on adenosine deaminase activity: I. Ben-Shooshan; Biochim. Biophys. Acta. 1587'' 21 (2002)'' Abstract;

Human serum dipeptidyl peptidase IV (DPPIV) and its unique properties: H. Shibuya-Saruta; J. Clin. Lab. Anal. 10'' 435 (1996)'' Abstract;

Activity of dipeptidyl peptidase IV and post-proline cleaving enzyme in sera from osteoporotic patients: H. Gotoh et al.; Clin. Chem. 34'' 2499 (1988)'' Abstract;